University Hospital Giessen Performs First Minimally Invasive, Robotic-Assisted Coronary Intervention in Germany

Siemens HealthineersThe University Hospital Giessen is the first hospital in Germany where a robotic system assists in a minimally invasive procedure to place a stent into a narrowed coronary artery to reopen it. This percutaneous coronary intervention (PCI) was carried out by the team of Prof. Holger Nef, Deputy Clinical Director Medical Clinic I, Cardiology and Angiology, University Giessen. To control interventional devices, doctors use the endovascular robotic system, CorPath® GRX (1) from Corindus, a Siemens Healthineers company, together with an Artis angiography system from Siemens Healthineers.

"Detailed imaging in combination with robotic-assisted intervention can provide increased precision to minimally invasive therapy. Especially complex procedures can be standardized and potentially provide better clinical results. I am very pleased that we were able to successfully use our imaging system and endovascular robotic platform at the University Hospital Giessen and Marburg in a procedure," said Doris Pommi, General Manager Cardiovascular Care at Siemens Healthineers.

Corindus' robotic system allows physicians to precisely control catheters, guidewires, balloons and stents with the help of integrated imaging for minimally invasive procedures. The doctor does not have to be physically next to the angiography table as usual, but can control the procedure via the system’s control module and is thus exposed to less radiation.

"The robotic system allows the precise positioning of interventional devices. This is crucial for the procedural success of the PCI procedure and can help improve long-term patient benefits. If coronary lesions are not fully covered by stents, this is a significant risk factor for follow-up interventions caused by re-stenosis," said Prof. Christian Hamm, Clinic Director Medical Clinic I, Cardiology/Angiology, University Giessen.

Technical advances in interventional cardiology can make it possible to successfully perform even more complex procedures routinely, like multi-vascular diseases, main stem stenosis, bifurcation stenosis or even re-openings of chronic closures. "Especially in these interventions, precision through robotic support, as well as the reduction of radiation exposure, can be of fundamental importance," said Prof. Holger Nef.

Coronary heart disease is one of the most common cardiovascular diseases in Western industrialized nations. Its consequences, such as acute heart attacks, are among the most common causes of death in Germany. In the treatment of acute and chronic coronary syndrome, PCI with stent implantation has established itself as the gold standard and is recommended in the European treatment guidelines.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.

About Corindus

Corindus, a Siemens Healthineers company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world.

1. The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed. Detailed information is available from the local Siemens Healthineers organization.

Most Popular Now

Artificial Intelligence: Unexpected Resu…

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics...

Printed Robots with Bones, Ligaments, an…

3D printing is advancing rapidly, and the range of materials that can be used has expanded considerably. While the technology was previously limited to fast-curing plastics, it has now been...

AI identifies Non-Smokers at High Risk f…

Using a routine chest X-ray image, an artificial intelligence (AI) tool can identify non-smokers who are at high risk for lung cancer, according to a study being presented next week...

Orchestrating the New World of AI in Hea…

Orion Health's UK and Ireland Customer Conference 2023 focused on the future potential and immediate, practical application of AI to healthcare - and gave delegates a first look at the...

Study Reveals Bias in AI Tools when Diag…

Machine learning algorithms designed to diagnose a common infection that affects women showed a diagnostic bias among ethnic groups, University of Florida researchers found. While artificial intelligence (AI) tools offer...

Researchers Take New AI Approach to Anal…

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue...

Medical AI Tool from UF, NVIDIA gets Hum…

A new artificial intelligence (AI) computer program created by researchers at the University of Florida and NVIDIA can generate doctors' notes so well that two physicians couldn't tell the difference...

Commission Opens Calls to Invest €42 Mil…

Today, the European Commission opened a new set of calls for proposals under the 2023-2024 Work Programmes of the Digital Europe Programme with a focus on advanced digital skills. The calls...

Bayer Championing Advancements in Radiol…

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence...

MEDICA and COMPAMED: Medical Technology …

13 - 16 November 2023, Düsseldorf, Germany. After four days of business, MEDICA and COMPAMED in Düsseldorf delivered impressive confirmation that they are excellent platforms for the worldwide medical technology business...

AI Predicts Developmental Paths in Prema…

Researchers at UMC Utrecht have developed an AI model to predict long-term outcome in extremely premature babies early in life. The model can identify which infants might face intellectual disability...

AI Paves Way for New Medicines

A team of researchers from LMU, ETH Zurich, and Roche Pharma Research and Early Development (pRED) Basel has used artificial intelligence (AI) to develop an innovative method that predicts the...